Xtandi
The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Xtandi in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Xtandi.
25
Global Revenue Ranking
Recent articles on PMLiVE featuring Xtandi
The phase 3 trial showed greater than 50% improvement in radiographic progression-free survival
Around 55,100 cases of prostate cancer are diagnosed in the UK every year
Up to 20% of patients will develop metastatic castration-resistant disease within five to seven years of diagnosis
Approximately 300,000 new cases of the disease are diagnosed in the US every year
Gastric cancer is currently the sixth-most common cause of cancer-related mortality in Europe
Up to 40% of patients who have undergone definitive prostate cancer treatment will experience biochemical recurrence within ten years
For nine out of ten patients with nmHSPC with high-risk BCR, their condition will progress into a metastatic disease
As part of the deal, Xyphos will combine its iGPS system with Kelonia’s ACCEL technology
An estimated 300 patients will be eligible for treatment with the PARP inhibitor
Approximately 470,000 new cases of prostate cancer were reported in Europe in 2020
More than 50,000 cases of the blood cancer are diagnosed each year in Europe
Xtandi is the first androgen receptor signalling inhibitor approved for this patient population
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology